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Summary: This paper describes the field performance of the Kodak EKTACHEM GLU/BUN Analyzer for glucose
and urea. NCCLS protocols PSEP-2,3 and 4 were used which enable manufacturers to establish perfonnance Claims
concerning the precision and accuracy of an analytical System. This multicentre trial used four analysers in four
European countries, United Kingdom, France, West Germany and Italy to assess within and between laboratory per-
formances.
Freeze dried control materials were used for the performance check experimerit PSEP-2 and for the replication experi-
ment PSEP-3. The replication study, although very time consuming, was straight förward to undertake and the results
were comparable between centres. Compliance with the protocol fbr comparison of methpds experinient PSEP-4 in
which laboratories used their own hospital patient samples was more difficult. The problems with obtaining suitable
samples and the performance of compaiative methods are discussed in detail.
Multizentrische europäische Prüfung des Kodak EKTACHEM GLU/BUNl)-Analyzers nach NCCLS1 ̂ Richtlinien und
ähnlichen Verfahren
Zusammenfassung: Die Leistung des Kodak EKTACHEM GLU/BUN^-Analyzers für Glucose und Harnstoff im täg-
lichen Einsat? wird beschrieben. Als Richtlinien für die Prüfung wurden die NCCLS^-Protokolle PSEP-2, 3 und 4,
die den Herstellern zur Ermittlung von Leistungsbereichen von analytischen Systemen hinsichtlich Präzision und Rich-
tigkeit dienen, angewandt. Zur Ermittlung der Leistungen innerhalb und zwischen Laboratorien umfaßte die multi-
zentrische Studie vier Geräte in vier europäischen Ländern: Großbritannien, Frankreich, Deutschland und Italien.
Lyophilisierte Kontrollmaterialien wurden Für den Versuch zur Prüfung der Leistung (PSEP-2) und den Wiedergabe-
versuch (PSEP-3) benutzt. Die Wiedergabestudie war, obwohl zeitaufwendig, einfach durchzufuhren und ergab
zwischen den Zentren vergleichbare Ergebnisse. Übereinstimmung mit dem Protokoll für den Methodenvergleichs-
Versuch PSEP-4, für den die Laboratorien Proben ihrer eigenen Krankenhauspatienten einsetzten, war schwieriger zu
erzielen. Die Problematik, geeignete Proben zu erhalten und die Leistung von Methoden vergleichend zu untersuchen,
wird ausführlich erörtert.
*) The abbreviation GLU is used here for glucose (!),
BUN = blood urea nitrogen.
2) NCCLS = National Comxnittee for Clinical Laboratory Stan-
dards (U.S.A.).
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Introduction
The Kodak EKTACHEM analytical System (l, 2) has
recently been introduced into the field of clinical
chemistry and Kodak EKTACHEM GLU/BUN Analyzers
for glucose and urea analyses are now in routine use in
a number of hospitals in the United States of America.
As part of the programme for testing the field perform-
ance of the analytical System, four hospital laboratories
in the United Kingdom, France, West Gerinany and
Italy used four separate analysers run according to
the manufacturers "Operators Manual" (3) over the
same period of time to carry out studies using the
National Committee for Clinical Laboratory Standards
(NCCLS) Protocol for Establishing Performance Claims
for Clinical Chemistry Methods (PSEP-2, 3 and 4) (4).
A previous evaluation of the Kodak EKTACHEM pro-
ducts has been published (5). The earlier NCCLS proto-
col PSEP-1 was available at that time but the study was
not on a multicentre basis. In this study the same
materials and protocols were used (apart from patient
samples) in all thev laboratories and this provided a
unique opportunity to assess within and between
laboratory performance of Kodak EKTACHEM pro-
ducts and to obtain practical experience using the proto-
coL Since it is essential that manufacturers work jointiy
with hospitals in the use of these protocols to establish
performance Claims we have included comments on their
practicability.
Materials and Methods
NCCLS protocol for establishing Performance Claims
for Clinical Chemistry methods
The protocol is in three sections (4). The sections and the
materials used are described below.
1. Performance Check Experiment PSEP-2
The protocol describes the control material to be used and
suggests that the materials selected should simulate the
chaiacteristics of human sera äs closely äs possible. HIGH, MID
and LOW concentrations should contain where possible analytes
at concentrations near the top of the linear ränge of the method,
near the middle of the ränge for healthy people and neär the
bottom of the linear ränge of the method. Construction of
control charts is described and these were established for the
test methods on the four sites and used thioughout subsequent
evaluation experiments. Triplicate anaiyses of the three levels
were run on forty occasions during the familiarisation period.
The control sera used were lyophilised human material provided
by Kodak for the LOW and the HIGH-levels and Wellcpmtrol II
(Wellcome Reagents Ltd., Kent, U.K.) for the MID level. This
data was used to construct mean and ränge charts. The mean
charts consist of a grand mean with upper and lower control
limits at ± 3 Standard deviätions. Range is defined äs the differ-
ence between the highest and lowest of triplicate readings. The
overall mean ränge is calculated with a control limit set at 2.57
times the mean ränge.
2. Replication Experiment PSEP-3
The criteria for choice of material at HIGH, MID and LOW
levels is äs described for PSEP-2. Nine sample sets of HIGH,
MID and LOW levels arelrün after the performance check
samples. The sample sets for the maxi, midi and mini experi-
ments are shown in table 1. The ordef of the nine sample sets
are chosen from random permutations provided in the protocol.
The replication (imprecisipn) protocol specifies a period of
twenty days and a total of forty analytical runs. The midi
Version was chosen because it detected carry over effects and
provided estimates of within run, between run within day,
between runs between day and total imprecisipn. For each
concentration level studied two different estimates öf within
run .and total imprecision are reqüired for presentation of
performance Claims. The first, designated point estiriiate, is
the actual Standard deviation obserVed in the experiment per-
formed and the second, designated tolerance limit, represents
the upper limit that with 95% confidence will contain the
estimate of Standard deviation from 99% of all similar
experiments.
Tab. 1. Sample sets for Replication Experiments PSEP-3.



























































The replication experiment used the three controls from the
performance check period tpgether with Pathonorm L
(Nygaärd, BDH Ppole, England) Wellcomtrol I (Wellcome
Reagents Ltd, Beckenham, England) and GEO A632 (General
Diagnostics, New Jersey, USA).
3. Comparison of Methods Experiment PSEP-4
In this experiment patient specimens are analysed by both
the test method and a comparative analytical method. A
suggested concentration distribution pf specimens for a number
of analytes is given in the protocol.
Table 2 gives the suggested distribution and the actual distri-
bution used for urea and glucose specimens. the comparative
methods used by each labpratory, the type Pf the specimens
collected, storage conditions and individual modifications to
the protocol are given in table 3.
Four sets of data have been used for regression analysis (tabs.
6 and 7). Set (A) includes results from all specimens; set (B)
exclüded specimens firstly, if the mean of any duplicate by
the Kodak EKTACHEM products was outside the dynamic
ränge specifled in the operators manual (3) that is for glucose
1.11-33.3 mmol/1 and urea 0.71-42.8 mmol/1. Secondly,
if the mean of any duplicate by the comparative method was
outside the manufacturers quoted dynamic ränge.
Set (C) is prepared by using the Standard error about the
regression line (syx) calculated from data set (B) to apply
» »
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the test for outliers whereby up to three pairs showing a
difference of greater than 3.5 times Syx can be excluded
before the final regression analysis. Set D gives the analysis
of Wellcome sera.
The regression statistics obtained on data set (C) are used to
calculate average bias (yc-xc, where yc is the test method value
at medical decision concentration xc) at different medical
decision concentrations. Tolerance limits are caleulated for
yc so that there is a 99% probabüity that 95% of the samples
are included within the upper and lower limits and total error
is estimated äs the absolute value of the largest difference
between the tolerance limits and xc. It is recommended that
the tolerance limits and total error be caleulated only for
medical decision concentrations closest to the mean of the
comparative method results.
It has been recommended that the linear regression procedures
should be restricted to those cases where the correlation coeffi-
cient (r) exceeds 0.99 (6) or that the ränge of values used is
adequate when the Standard deviation of the comparative method
values (SDX) is greater than seven time (SyX) (7). Values for both r
and SDx/syx are included with regression statistics.
Wellcome Group Quality Control Programme
The multi-level lyophilised material available from the pro-
gramme was used, firstly to obtain Information on the perform-
ance of comparative methods in each laboratory relative to that
obtained by previous participants in the scheme, secondly to pro-
vide Information on the performance of the EKTACHEM
analyzer from laboratory to laboratory, and thirdly to give
comparison data additional to that from patient specimens.
Samples previously sent out by the scheme from 16 October
1978-26 March 1979 were analysed by the comparative and
Kodak methods at each site. Two dupücate sets of twelve lyo-
philised bovine sera were provided and a sample for analysis taken
from each of the twenty-four bottles after reconstitution, giving
twelve duplicate analyses for each analyte.
Analysis of the twelve samples by laboratories participating in
the scheme is normally spread over a six month period and the
analysis of results returned includes the overall mean for each
analyte, that is the mean of all results returned, with results
greater than three Standard deviations from the mean excluded,
and method means which represent the mean of all results from
laboratories with a particular method classification. The overall
mean values in the samples used ranged from 3.40 to 13.77
mmöl/1 for glucose and for urea from 5.21 to 23.61 mmol/1. The
material in the scheme came from four pools. Different amounts
of serum are dispensed to provide each sample and äs an identical
volume of fluid is recommended for reconstitution this results in
different analyte concentrations.








U.K. Glucose oxidase2)/AAl Diacetyl mon-
oxime5)/AAl
France Glucose oxidase/SMA6 Diacetyl mon-
Hexokinase/GEMSAEC oxime/SMA6
Fluoride oxalate plasma Specimens pre-selected, frozen, rerun dupli-
(glucose), serum (urea) cates, one run/day









Fresh specimens, replicate l, a.m. run,
replicate 2, p.m. run
Specimens pre-selected, frozen, rerun dupli-
cates in two runs/day
*) AAl/Technicon AutoAnalyser Mk. l
SMA/Technicon Sequential Multichannel Analyser
ACA/Dupont Automatic Clinical Analyser
GEMSAEC/Centrifugal Analyser
2) Samples > 20 mmol/1 diluted
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Results
NCCLS Protocol
L Replication Experiment (PSEP-3)
Tables 4 and 5 give the analysis of variance (ANOVA)
results for the replication experiment. These tables
include the mean value (mmol/1) of the concentration
level studied, the point estimates of Standard deviation
and degrees of freedom (df). Tolerance limit estimates
of Standard deviation are given for within run and total
imprecision.
2. Comparisonof Methods Experiment (PSEP-4)
Tables 6 and 7 give the regression statisties together with
correlation coefficient and the ratio SDx/SyX for patient
samples used in the comparison of methods experiment.
The preparation of data sets A, B and C is described in
the Materials and Methods section. Regression statisties
from data sets A and C were used to calcüiate the accuracy
performance Claims given in table 8.










































































































































































Abbreviations used: (df) degrees of freedom, S.D. point estimate of Standard deviation.










































































































































































Abbreviations used: (df) degrees of freedom, S.D. point estimate of Standard deviation.
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Tab. 6. Regression analysis of data for glucose Comparative Methods (x) and Kodak EKTACHEM (y)































































































































































































































1) See Materials and Methods for explanations.
2) AAl/Technicon AutoAnalyser Mk. l
SMA/Technical Sequential Multichannel Analyser
ACA/Dupont Automatic Clinical Analyser
GEMSAEC/Centrifugal Analyser
3) Asterisk denotes significant difference from slope of 1.00 or zero intercept (95 % confidence limits).
Tab. 7. Regression analysis of data for urea Comparative Methods (x) and Kodak EKTACHEM (y) for patient samples and










































































































































































































1) See materials and methqds for explanation.
2) AAl/Technicon AutoAnalyser Mk. l
SMA/Technical Sequential Multichannel Analyser
ACA/Dupont Automatic Clinical Analyser
GEMSAEC/Centrifugal Analyser
3) Asterisk denotes significant difference from slope of 1.00 or zero intercept (95% confidence limits).
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Wellcome Group Quality Control Programme
Table 9 gives the regression statistics which indicate the
Performance of the comparative methods (y) in each
laboratory against the appropriate method mean for
each laboratory.
Tables 10 and 11 show the regression statistics for the
Performance of the EKTACHEM analyzer from labor-
atory to laboratory and tables 6 and 7 give in data sets D
additional Information from each laboratory for the
comparative method with the EKTACHEM analyzer.
No exclusion criteria were applied to the results in this
section äs the riurnber of samples was small. The ratio
SDx/Syx in every case was well in excess of 7.0 and no
pairs showed a difference in excess of S.Srtimes SyX.



































































































































































!) AAl/Technicon Auto Analyser Mk. l
SMA/Technicon Sequential Multichannel Analyer
ACA/Dupont Automatic Clinical Analyser
GEMSAEC/Centrifugal Analyser
2) See text for explanation.
























































U.K. Diacetyl monoxime/AAl 12



























*) AAl/Technicon AutoAnalyser Mk. l
SMA/Technicon Sequential Multichannel Analyser
ACA/Dupont Automatic Clinical Analyser
GEMSAEC/Centrifugal Analyser
2) Asterisk indicates significantly different from 1.00 or zero at 95% confidence limits.
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*) Asterisk indicates significantly different from 1.00 at 95% confidence limits.































































































































*) Asterix indicates significantly different from 1.0 at 95% confidence limits,
Discussion
Problems encountered with PSEP-2, 3 and 4
The establishment of performance Claims for Clinical
Chemical Methods has become a major expense for manu-
facturers of clinical chemistry Systems and a time con-
suming occupation for skilled laboratory workers.
In these activities, however, there are complex problems,
for manufacturers and clinical chemistry laboratories
alike and the publication of proposed Standards PSEP-
2,3 and 4 by the NCCLS represent an iniportant con-
tribütion to progress in this field.
This paper reports sojne of our experience with these
Standards and the data derived from our work. The
PSEP-2 and 3 Standards although time consuming, pre-
sented few difficulties in execution at the different
sites. However, all siies encountered some difficulties
in carrying out the proposed Standard for the Compar-
ison of Methods Experiment (PSEP-4). The difficulties
related on the one hand to the selection of patient
specimens and their analysis according to the protocol
and on the other hand to the performance of the
comparative methods during the period of study.
The overview öf the Cqmparison of Methods Experi-
ment suggests that "at least 100 fresh patient's speci-
mens should be analysed in duplicate by both the test
method and the comparative analytical method. The
experiment must cover a period of at least 4 days,
which permits a maximum of 25 specimens to be
analysed in one day, or it can extend over a longer
period of time if that is convenient for the evaluation
stüdy". Recommendations for the selection öf patients
specimens are given and one suggested distribution is
shown in table 2.
It is clear that all sites encountered difficulties in
selection of specimens and the laboratories in Italy and
the U.K. were only able to comply with the suggested
distribution by preselecting specimens and freezing
them prior to subsequent duplicate analysis (tab. 3).
With the exception of the laboratory in France all sites
J. Gin. Chem. Clin. Biochem. /Vol. 20,1982 / No. 4
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analysed the specimens in duplicate. The laboratory in
France however ran nearly twice the number of speci-
mens äs the other laboratories and äs a result regression
estimates will not be markedly affected. However, only
the German laboratory complied with the stipulation
that the replicates should be in separate runs. One
penalty of not running duplicates is the failure to pro-
duce within run estimates of imprecision for human sera
for the test and comparative methods. The information
is important for evaluation of the comparative method
and for its comparison with the test method.
Additionally, these estimates of within run imprecision
can be usefully compared with those obtained in the
replication experiment using the lyophilised material.
If the patient specimens in the German laboratory are
replicated between run rather than within run, different
estimates of precision are obtained which are not
strictly comparable.
The amount of specimen required in order to perform
duplicate analysis* by the test and comparative method
represents a major problem if the test and/or compara-
tive methods require substantial amounts of serum or
plasma. The use of this protocol for evaluation of
multichannel Systems may present special difficulties,
although one such evaluation has recently been
published (9).
There is a tendency when selecting specimens for analysis
to encounter difficulties at the ends of the ränge. This
can lead to the multiple selection of specimens from
one patient so that although the number of specimens
required is fulfilled the variability represented by those
specimens is reduced. If this were to become a major
feature of selection then it might result in falsely low
estimates of syx which would markedly improve the
accuracy performance Claims. It is interesting in this
connection to compare the regression statistics for
comparison of methods for the bovine material from
the Wellcome Scheme (tabs 6 and 7 data sets D) with
those obtained on patient specimens (data sets C).
Bearing in mind the recognised problems associated
with commutability of human specimens and samples
from animal sources together with the small number
of Wellcome samples used, the majority of estimates
of slope and intercept are in good agreement with those
obtained with patient specimens, However, the value
for syx in all laboratories for urea and glucose using
Wellcome material is markedly lower than the value on
patient specimens. This reflects the fact that the Well-
come material is taken from four homogenous pools
and the smaller ränge covered.
If in excess of fifty quality control samples were used
in a comparison of methods and commutability were
satisfactory the Standard deviation of the estimates of
slope and intercept would be markedly improved (8)
but analysis of lyophilised material from different
sources can never replace patient specimens in estima-
tion of the Standard error of the regression line.
France used lithium heparin plasma specimens for
glucose and urea analyses and the United Kingdom used
fluoride oxalate plasma for glucose. Carermust be taken
to ensure that plasma specimens prepared in this way
are obtained from blood specimens which had the re-
commended amounts of anticoagulänt added. High con-
centrations, resulting from inadequate filling of a
specimen Container, can adversely affect measurement
by a test or comparative method.
The choice and control of the comparative method
represents the second major probleih in the comparison
of methods experiment and whereas the protocol
discusses briefly the factors affecting the choice of
ä comparative or reference method it does not provide
guidance äs to the control of that method during the
period of study. The data preserited in table 9 repre-
sents an attempt to provide some Information about
the bias of the comparative methods. The significänt
(95% confidence limits) positive intercept öf 0.4101
in the glucose data from Italy indicates the presence
of constant error whereas the glucose data from France
and the urea data from Italy indicate ä significänt pro-
portional errpr in these methods when compared with
their appropriate method means. When an individual
laboratory results are compared with method means it
must be remembered that the method mean codes used
in this instance do not define a group of laboratories
using a particular Instrument with a particular method
but perhaps äs in the case of the code for the hexo-
kinase/glucose method it contains on average 114
laboratories using Instruments from %t least nine
different manufacturers some employing discrete
analysis and some continuous flow. Therefore caution
must be exercised when interpreting such a comparison.
Performance of the Kodak EKTACHEM GL tf/BUN
Analyzer and preparation of Performance Claims
The Kodak EKTACHEM GLU/BUN änalyzer perfonned
well on all sites äs judged by estimates of imprecision by
using the proposed Standard PSEPJ (tab. 4 and 5), and
analysis of data from all laboratories indicates the veiy
small contribution made to the overall variance by the
laboratory to laboratory component. The differences in
tolerance limits and estimates of total error (tab. 8)
obtained from the comparison öf methods Standard
PSEP-4 are influenced by the way in which data is
analysed. The performance of the comparative methods
is also important and makes a simultaneous multicentre
study in evaluation of methods particularly valüäble
when Claims for a product are put forward.
In the preparation of accuracy performance Claims it is '
clearthat calculation of bias is dependent on reliable
estimates of slope and intercept and thfljt the tolerance
J. Clin. Chem. Clin. Biochem. / Vol. 20,1982 / No, 4
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limits are additionally dependent on the Standard error
about the regression line (SyX). It is interesting in tables
6 and 7 to see that the rule goveming the exclusion of
outliers can either eliminate or reduce outliers (compare
data sets B with C) or because of the redefinition of syx
implicit in creating a new data set can lead to the same
numbers of outliers still existing (see German data set B
and C for glucose tab. 6). Preparation of data in the
manner recommended will sometimes lead to a reduc-
tion in the ränge of samples analysed and additionally
the rernoval of outliers will reduce the value of sxy. For
Performance Claims to be comparable these factors must
be taken into account. This effect can be seen by com-
paring the performance claims based on the whole data
set A with those given for the prepared data set C.
The protocol suggested that tolerance limits and total
error be calculated only for medical decision eoncentra-
tions closest to the mean of the comparative method
data (x) table 8 shows that for glucose (data sets C) this
requirement is reasonably well fulfdled. For the medical
decision concentration of 6.6 mmol/1 values of ränge
from 5.96 to 7.31 mmol/1. However for urea the Situation
is less than satisfactory with mean values of ranging
from 7.76 to 12.88 mmol/i for a medical decision
concentration of 9.60 mmol/1. This problem has how-
ever already appeared in the litefatüre (9) with medical
decision concentrations of 1100 mg/1 (6.1 mmol/1) for
glucose having tolerance limits and total error quoted
when the mean of comparative or reference method was
1670 mg/1 (9.3 mmol/1) and 1600 mg/1 (8.9 mmol/1)
respectively and for a medical decision concentration of
250 mg/1 ((8.9 mmol/i) for ürea nitrogen with mean of
at 512 mg/1 (18.3 mmol/1). It will be necessary to in-
dicate how close is close if performance Claims are to be
of value. The mean ofthe comparätive method (x) shoüld
be given in an accuracy performance cläim in Order to
avoid misunderstanding.
The Wellcome material was also üsed tö provide äddi-
tional data on EKTACHEM products from site to site
(tab. 10 and 11). The estimates of slope were signifi-
cantly different from l .00 (95% confidence limits) for
both urea and glucose between France and Italy whereas
no significant differences from zero were observed for
estimates of intercept. These differences are not how-
ever clearly reflected in the mean values of material
used in the replicatiOn study (Tab. 4 and 5).
Conclusions
The proposed Standards PSEP-2,3 and 4 have proved a
üseful basis on which to establish this multi-centre trial
of the Kodak EKTACHEM GLU/BUN analyzer. The
difficulties associated particularly with PSEP-4 have
been fully discussed. It is suggested that the proposed
Standard, PSEP-4 would be imprqved by inclusion of
some basic criteria for evaluafion of the comparative
method against other laboratories in form of methods
means. It is in this area that manufacturers are most
vulnerable to Claims made for or against their products
by laboratories using inadequätely controlled compara-
tive or reference techniques.
Because of the difficulties associated with obtaining
patient samples and the labile nature of some analytes,
manufacturers will always require the assistance of
clinical chemistry laboratories in the establishment
of performance Claims, but pur experience suggests,
that this work shoüld not be undertaken lightly by
laboratories and that manufacturers would be advised
to assess the resources of any chosen site carefully
befbre proceeding.
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Im Gegensatz zu RIA benötigen Sie bei
ELISA* keine radioaktiven Substanzen. Sie
haben keine Probleme mit dem Personen-
schutz und der Entsorgung. Den ELISA-Meß-
platz können Sie in jedem Labor sofort
einsetzen.
2. Bessere Analysenqualität
Die Probenaufbereitung läuft automatisch im
15-Sekunden-Rhythmus. Das verringert den
Arbeitsaufwand und nimmt Ihnen die Einhal-
tung des Zeittaktes ab. Sie verbessern die
Analysenqualität und erhöhen den Proben-
durchsatz.
3. Keine Rechenarbeit
Der programmierbare Rechner wertet die
Messungen aus. Sie erhalten ohne Rechen-




Der Meßplatz ist nach dem Bausteinprinzip
aufgebaut. Das ermöglicht Ihnen die Parallel-
nutzung für ELISA und weitere Endpunkt-
methoden.
*Enzymun-Testse>T3,14, TBK, Insulin, Digoxin,
Boehringer Mannheim GmbH





Das Coatron, eine Neuentwicklung der
LRE Medizintechnik, ist das automa-
tische Gerinnungsmeßgerät für das
mittlere und das große Labor. Coatron
ermöglicht einen hohen Probendurch-






















950 nm. Fremdlicht führt
nicht zur Verfälschung
der Meßergebnisse.
zision und Richtigkeit sowie optimaler
Reproduzierbarkeit der Ergebnisse.
Ein echter Problemloser also, Das






in einem festen Zeittakt
von Position zu Position.
Manuell· Möglichkeit der






auf 37°C im Inkubatöf-
biock erst kurz vor der
Messung,
Coatron. Ein Synonym für Fortschritt
in der Gerinnungsdiagnostik.
Mehr Effizienz und! Wirtschaftlichkeit
im medizinischen Labor.
Der Probendurchsatz
beträgt für die Para-
meter PT und TZ 90/h,
füfPTT40/h.
Wir stellen für Sie aus:
Analytica 82, München,
Halle 16, Stand N r. 16 805
LRE RELAIS+ELEKTRONIK GMBH, Linprunstraße 16, 8000 München 2, Telefon: (089) 523020, Telex: 522190
